ENHERTU® (FAM-TRASTUZUMAB DERUXTECAN-NXKI) PLUS PERTUZUMAB APPROVED IN THE US AS FIRST NEW TREATMENT IN A DECADE FOR THE 1ST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

Reuters · 1d ago

Please log in to view news